OncoCyte Corporation (AMEX: OCX) was founded in 2009 and is headquartered in Alameda, California, USA, with 16 full-time employees. It is a company focused on the development and commercialization of new and non-invasive blood and urine (liquid biopsy) diagnostic tests. In order to detect cancer early. It is a subsidiary of BioTime, Inc.
OncoCyte Corporation (OCX):
OncoCyte Corporation focuses on the discovery, development and commercialization of new non-invasive liquid biopsy diagnostics for early detection of cancer. OncoCyte believes that better and earlier detection of cancer through liquid biopsy will:
1. Improve the treatment effect of patients
2. Extend the life expectancy of cancer patients
3. Significantly reduce medical costs
Currently, cancer diagnostic tests still rely mainly on scanning, and then relying on invasive surgical procedures to obtain tissue samples to determine whether the tumor is benign or malignant. These invasive tests are expensive and time-consuming, and can cause patient anxiety and uncertainty in the doctor’s diagnosis.
OncoCyte Corporation’s next-generation liquid biopsy diagnosis will use blood or urine samples to detect the presence of cancer. And this diagnosis: simple, accurate, fast and non-invasive.
The molecular cancer diagnosis under development by OncoCyte Corporation mainly uses the discovery platform to identify genetic markers in various types of cancer. The diagnostic test developed by the company is used to detect various cancers, including lung cancer, bladder cancer and breast cancer.
The company’s product development progress (January 2018) :